303 related articles for article (PubMed ID: 27132172)
1. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B.
Blank A; Markert C; Hohmann N; Carls A; Mikus G; Lehr T; Alexandrov A; Haag M; Schwab M; Urban S; Haefeli WE
J Hepatol; 2016 Sep; 65(3):483-9. PubMed ID: 27132172
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.
Bogomolov P; Alexandrov A; Voronkova N; Macievich M; Kokina K; Petrachenkova M; Lehr T; Lempp FA; Wedemeyer H; Haag M; Schwab M; Haefeli WE; Blank A; Urban S
J Hepatol; 2016 Sep; 65(3):490-8. PubMed ID: 27132170
[TBL] [Abstract][Full Text] [Related]
3. Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro.
Blank A; Meier K; Urban S; Haefeli WE; Weiss J
Antivir Ther; 2018; 23(3):267-275. PubMed ID: 29134945
[TBL] [Abstract][Full Text] [Related]
4. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.
Volz T; Allweiss L; Ben MBarek M; Warlich M; Lohse AW; Pollok JM; Alexandrov A; Urban S; Petersen J; Lütgehetmann M; Dandri M
J Hepatol; 2013 May; 58(5):861-7. PubMed ID: 23246506
[TBL] [Abstract][Full Text] [Related]
5. Clinical effects of NTCP-inhibitor myrcludex B.
Cheng D; Han B; Zhang W; Wu W
J Viral Hepat; 2021 Jun; 28(6):852-858. PubMed ID: 33599010
[TBL] [Abstract][Full Text] [Related]
6. The NTCP-inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics.
Blank A; Eidam A; Haag M; Hohmann N; Burhenne J; Schwab M; van de Graaf S; Meyer MR; Maurer HH; Meier K; Weiss J; Bruckner T; Alexandrov A; Urban S; Mikus G; Haefeli WE
Clin Pharmacol Ther; 2018 Feb; 103(2):341-348. PubMed ID: 28543042
[TBL] [Abstract][Full Text] [Related]
7. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.
Lütgehetmann M; Mancke LV; Volz T; Helbig M; Allweiss L; Bornscheuer T; Pollok JM; Lohse AW; Petersen J; Urban S; Dandri M
Hepatology; 2012 Mar; 55(3):685-94. PubMed ID: 22031488
[TBL] [Abstract][Full Text] [Related]
8. Myrcludex B, a novel therapy for chronic hepatitis D?
Rizzetto M; Niro GA
J Hepatol; 2016 Sep; 65(3):465-6. PubMed ID: 27538763
[No Abstract] [Full Text] [Related]
9. [Study of the inhibitory effect of cell entry inhibitory myrcludex-B synthetic peptide on HepaRG cells infected with hepatitis B virus in an in vitro infection model].
Yang JQ; Li H
Zhonghua Gan Zang Bing Za Zhi; 2020 Jun; 28(6):499-503. PubMed ID: 32660179
[No Abstract] [Full Text] [Related]
10. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.
Ni Y; Lempp FA; Mehrle S; Nkongolo S; Kaufman C; Fälth M; Stindt J; Königer C; Nassal M; Kubitz R; Sültmann H; Urban S
Gastroenterology; 2014 Apr; 146(4):1070-83. PubMed ID: 24361467
[TBL] [Abstract][Full Text] [Related]
11. Investigational drugs in development for Hepatitis D.
Rizzetto M
Expert Opin Investig Drugs; 2017 Sep; 26(9):999-1005. PubMed ID: 28730878
[TBL] [Abstract][Full Text] [Related]
12. Emerging concepts for the treatment of hepatitis delta.
Elazar M; Glenn JS
Curr Opin Virol; 2017 Jun; 24():55-59. PubMed ID: 28475945
[TBL] [Abstract][Full Text] [Related]
13. A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B.
Uhl P; Helm F; Hofhaus G; Brings S; Kaufman C; Leotta K; Urban S; Haberkorn U; Mier W; Fricker G
Eur J Pharm Biopharm; 2016 Jun; 103():159-166. PubMed ID: 27049970
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.
Nkongolo S; Ni Y; Lempp FA; Kaufman C; Lindner T; Esser-Nobis K; Lohmann V; Mier W; Mehrle S; Urban S
J Hepatol; 2014 Apr; 60(4):723-31. PubMed ID: 24295872
[TBL] [Abstract][Full Text] [Related]
15. Strategies to inhibit entry of HBV and HDV into hepatocytes.
Urban S; Bartenschlager R; Kubitz R; Zoulim F
Gastroenterology; 2014 Jul; 147(1):48-64. PubMed ID: 24768844
[TBL] [Abstract][Full Text] [Related]
16. New treatment options for delta virus: Is a cure in sight?
Yurdaydin C
J Viral Hepat; 2019 Jun; 26(6):618-626. PubMed ID: 30771261
[TBL] [Abstract][Full Text] [Related]
17. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.
Kaneko M; Watashi K; Kamisuki S; Matsunaga H; Iwamoto M; Kawai F; Ohashi H; Tsukuda S; Shimura S; Suzuki R; Aizaki H; Sugiyama M; Park SY; Ito T; Ohtani N; Sugawara F; Tanaka Y; Mizokami M; Sureau C; Wakita T
J Virol; 2015 Dec; 89(23):11945-53. PubMed ID: 26378168
[TBL] [Abstract][Full Text] [Related]
18. [Is there hope for hepatitis delta ?].
Guglielmi S; Frossard JL; Negro F
Rev Med Suisse; 2016 Aug; 12(528):1415-1418. PubMed ID: 28675280
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts.
Schieck A; Schulze A; Gähler C; Müller T; Haberkorn U; Alexandrov A; Urban S; Mier W
Hepatology; 2013 Jul; 58(1):43-53. PubMed ID: 23292963
[TBL] [Abstract][Full Text] [Related]
20. Management of hepatitis delta: Need for novel therapeutic options.
Abbas Z; Abbas M
World J Gastroenterol; 2015 Aug; 21(32):9461-5. PubMed ID: 26327754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
